Oncogene Protein p21(ras)
"Oncogene Protein p21(ras)" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Transforming protein encoded by ras oncogenes. Point mutations in the cellular ras gene (c-ras) can also result in a mutant p21 protein that can transform mammalian cells. Oncogene protein p21(ras) has been directly implicated in human neoplasms, perhaps accounting for as much as 15-20% of all human tumors. This enzyme was formerly listed as EC 3.6.1.47.
Descriptor ID |
D015689
|
MeSH Number(s) |
D08.811.277.040.330.300.400.500.300 D12.644.360.525.500.300 D12.776.157.325.515.500.300 D12.776.476.525.500.300 D12.776.624.664.520.750.710 D12.776.964.700.750.710 D12.776.964.775.750.710
|
Concept/Terms |
Oncogene Protein p21(ras)- Oncogene Protein p21(ras)
- p21 Transforming Viral Protein
- p21 v-H-ras
- p21 v H ras
- v-H-ras, p21
- p21(v-H-ras)
- p21 v-Ki-ras
- p21 v Ki ras
- v-Ki-ras, p21
- p21 v-ras
- p21 v ras
- v-ras, p21
- ras Oncogene p21 Product
- ras Oncogene Product p21
- p21 v-Ha-ras
- p21 v Ha ras
- v-Ha-ras, p21
- p21(v-Ha-ras)
- p21(v-K-ras)
- ras Oncogene Protein p21
- p21(v-Ki-ras)
|
Below are MeSH descriptors whose meaning is more general than "Oncogene Protein p21(ras)".
Below are MeSH descriptors whose meaning is more specific than "Oncogene Protein p21(ras)".
This graph shows the total number of publications written about "Oncogene Protein p21(ras)" by people in this website by year, and whether "Oncogene Protein p21(ras)" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 3 | 1 | 4 | 1996 | 1 | 0 | 1 | 2004 | 0 | 2 | 2 | 2007 | 1 | 0 | 1 | 2012 | 0 | 1 | 1 | 2013 | 0 | 1 | 1 | 2015 | 1 | 0 | 1 | 2017 | 0 | 2 | 2 | 2019 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Oncogene Protein p21(ras)" by people in Profiles.
-
Rotow JK, Gui P, Wu W, Raymond VM, Lanman RB, Kaye FJ, Peled N, Fece de la Cruz F, Nadres B, Corcoran RB, Yeh I, Bastian BC, Starostik P, Newsom K, Olivas VR, Wolff AM, Fraser JS, Collisson EA, McCoach CE, Camidge DR, Pacheco J, Bazhenova L, Li T, Bivona TG, Blakely CM. Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer. Clin Cancer Res. 2020 01 15; 26(2):439-449.
-
Rossman MJ, Kaplon RE, Hill SD, McNamara MN, Santos-Parker JR, Pierce GL, Seals DR, Donato AJ. Endothelial cell senescence with aging in healthy humans: prevention by habitual exercise and relation to vascular endothelial function. Am J Physiol Heart Circ Physiol. 2017 Nov 01; 313(5):H890-H895.
-
Arnold MA, Barr FG. Molecular diagnostics in the management of rhabdomyosarcoma. Expert Rev Mol Diagn. 2017 02; 17(2):189-194.
-
Yu C, Huo X, Agoston AT, Zhang X, Theiss AL, Cheng E, Zhang Q, Zaika A, Pham TH, Wang DH, Lobie PE, Odze RD, Spechler SJ, Souza RF. Mitochondrial STAT3 contributes to transformation of Barrett's epithelial cells that express oncogenic Ras in a p53-independent fashion. Am J Physiol Gastrointest Liver Physiol. 2015 Aug 01; 309(3):G146-61.
-
Cheong JK, Zhang F, Chua PJ, Bay BH, Thorburn A, Virshup DM. Casein kinase 1a-dependent feedback loop controls autophagy in RAS-driven cancers. J Clin Invest. 2015 Apr; 125(4):1401-18.
-
Bitler BG, Fink LS, Wei Z, Peterson JR, Zhang R. A high-content screening assay for small-molecule modulators of oncogene-induced senescence. J Biomol Screen. 2013 Oct; 18(9):1054-61.
-
Kern HB, Niemeyer BF, Parrish JK, Kerr CA, Yaghi NK, Prescott JD, Gutierrez-Hartmann A, Jedlicka P. Control of MicroRNA-21 expression in colorectal cancer cells by oncogenic epidermal growth factor/Ras signaling and Ets transcription factors. DNA Cell Biol. 2012 Aug; 31(8):1403-11.
-
Pincus MR, Fenelus M, Sarafraz-Yazdi E, Adler V, Bowne W, Michl J. Anti-cancer peptides from ras-p21 and p53 proteins. Curr Pharm Des. 2011; 17(25):2677-98.
-
Jean A, Gutierrez-Hartmann A, Duval DL. A Pit-1 threonine 220 phosphomimic reduces binding to monomeric DNA sites to inhibit Ras and estrogen stimulation of the prolactin gene promoter. Mol Endocrinol. 2010 Jan; 24(1):91-103.
-
Adler V, Bowne W, Michl J, Sookraj KA, Ikram K, Pestka S, Izotova L, Zenilman M, Friedman FK, Qu Y, Pincus MR. Site-specific phosphorylation of raf in cells containing oncogenic ras-p21 is likely mediated by jun-N-terminal kinase. Ann Clin Lab Sci. 2008; 38(1):47-56.
|
People People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|